(HealthDay News) — The rate of major adverse cardiovascular events is higher in patients with diabetes and multivessel coronary artery disease treated with insulin vs. those not treated with insulin, according to a study published in the Journal of the American College of Cardiology.
George D. Dangas, MD, PhD, from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues compared percutaneous coronary intervention (PCI) vs. coronary artery bypass graft surgery (CABG) in 1,850 participants who had an index revascularization procedure performed (956 underwent PCI with drug-eluting stents [DES] and 894 underwent CABG).
Nearly one-third of patients (32.5%) had insulin-treated diabetes (PCI/DES, 325 patients; CABG, 277 patients).
The researchers found that the overall 5-year event rate of death/stroke/myocardial infarction (MI) was significantly higher in insulin-treated diabetes vs. non-insulin-treated diabetes patients (28.7% vs. 19.5%; P<.001).
This difference remained, even after adjustment for baseline factors, including angiographic complexity and revascularization treatment group (death/stroke/MI composite HR=1.35; 95% CI, 1.06-1.73; P=.014).
For the composite endpoint, CABG was superior to PCI/DES in both diabetes types, with a similar magnitude of treatment effect (P=.40) for insulin-treated diabetes (PCI vs. CABG HR=1.21; 95% CI, 0.87-.69) and non-insulin-treated diabetes patients (PCI vs. CABG HR=1.46; 95% CI, 1.10=1.94).
“We did not detect a significant difference in the magnitude of PCI vs. CABG treatment effect for patients treated with insulin and those not treated with insulin,” concluded the authors.